Login to Your Account

Clinic Roundup

Friday, August 17, 2012

• Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, reported preliminary results from a Phase I dose-ranging study of LX2931, an inhibitor of sphingosine-1-phosphate lyase, in rheumatoid arthritis. The compound was well tolerated at all doses evaluated, with no serious adverse events.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription